Optical Activation of the Dorsal Horn of the Thoracic Spinal Cord Prevents Ventricular Arrhythmias in Acute Myocardial Ischemia-Reperfusion Rats
Brief intro:
- Author: Yong Wu, Zhongxu Luo, Zhengtao Hu, Kun Lv, Yinhua Liu, and Deguo Wang
- Journal: Frontiers in Cardiovascular Medicine
- Doi: https://www.doi.org/10.3389/fcvm.2022.753959
- Publication Date: 2022 Feb 7
Products/Services used in the paper
Quotation shows PackGene:AAV9-containing Ca(2+)/calmodulin-activated protein kinase II-a (CaMKIIa) prompter with or without -hChR2(H134R) (PackGene Biotech, 10^13 vg/ml) was drawn up into a 10 μl Hamilton syringe with a glass pipette and pulled to a 20μm tip (Hamilton, Shanghai, Ch). Then AAVs (3 μl) were injected into the dorsal horn (0.5mm depth) under control by a stereotaxic micromanipulator through previously reported methods
Research Field:heart
AAV Serotype:AAV9
Targeted organ:heart
Animal or cell line strain:Adult male rats (Sprague Dawley)
Abstract
Background and ObjectivesSpinal cord stimulation can prevent myocardial ischemia and reperfusion arrhythmias, but the relevant neurons and mechanisms remain unknown. Thus, this study applied optogenetic techniques to selectively activate glutamatergic neurons at the thoracic spinal cord (T1 segment) for examining the anti-arrhythmia effects during acute myocardial ischemic-reperfusion.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
